REGEnLIFE is stepping up its research into Alzheimer’s and sports concussions
Summary
REGEnLIFE (8 employees) specializes in the research and development of innovative technologies in photomedicine for the prevention and treatment of neurodegenerative diseases and has just completed a fundraiser of three million euros. The Montpellier medical technology company benefits from the support of around twenty investors, Bpifrance and the Occitania region, and finds itself in the third round of financing every two years.Targeting both the brain and the gut, the Montpellier medical technology company is working on the development of a non-invasive photomedical technology based in particular on the emission of combined infrared waves at the level of the skull and abdomen using a helmet and a chest plate.REGEnLIFE is involved in the treatment of Alzheimers disease and will start a new phase of studies next month in Toulouse, this time more comprehensive: it will carry out double-blind studies for several months on around a hundred patients with a mild to moderate form of Alzheimers disease.We will be tracking the biological markers of inflammation that are very specific to the disease, explains Patrice Cristofini. In fact, an athlete can withstand blows that produce an acceleration in the skull equivalent to that experienced when a car crashes into a wall at a speed of 60 to 80 km/h. When a player leaves the field, there isnt much to do other than rest, possibly taking medication for pain relief and, in the event of a more serious concussion, getting an imaging test. The methodology has been published in scientific journals.On the way to an international assignmentIn a global neurostimulation market valued at $20 billion in 2022 and projected to grow at a compound annual growth rate of 20% between 2023 and 2028 (Source: Reports Insights Consulting), medtech wants to take its place.REGEnLIFE then plans to conduct a fundraiser of 40 million euros from 2025.